Ajooni Biotech Limited has informed the Exchange about change in Management
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech Limited has re-appointed Mr. Jasjot Singh as its Managing Director for a fresh 5-year term effective April 1, 2025. Shareholders approved the re-appointment along with an increase in his remuneration via a special resolution at the 15th Annual General Meeting held on September 29, 2025. Mr. Jasjot Singh holds an MBA in Finance from Oxford University and has over 16 years of experience in finance, taxation, and the cattle feed supplement business. The disclosure confirms he is not related to any existing director on the board and is not debarred from holding office by SEBI or any other authority.
This is a continuity event rather than a disruptive change — the existing Managing Director is being retained with a longer tenure and higher pay, which provides leadership stability for shareholders. The increase in MD remuneration may be a minor governance point for small investors to note but is not unusual for re-appointments.